Shattuck Labs Inc
STTK1.930USD
-0.060-3.02%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
92.45MMarket Cap
LossP/E TTM
More Details of Shattuck Labs Inc Company
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
Shattuck Labs Inc Info
Ticker SymbolSTTK
Company nameShattuck Labs Inc
IPO dateOct 09, 2020
CEODr. Taylor Schreiber, M.D., Ph.D.
Number of employees44
Security typeOrdinary Share
Fiscal year-endOct 09
Address500 W. 5Th Street
CityAUSTIN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code78701
Phone15129004690
Websitehttps://www.shattucklabs.com/
Ticker SymbolSTTK
IPO dateOct 09, 2020
CEODr. Taylor Schreiber, M.D., Ph.D.
Company Executives of Shattuck Labs Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
+36.07%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
86.28K
+17.43%
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
81.47K
-8.97%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Mr. Conor Richardson, CPA
Mr. Conor Richardson, CPA
Senior Director, Finance & Investor Relations
Senior Director, Finance & Investor Relations
--
--
Dr. Clay Siegall, Ph.D.
Dr. Clay Siegall, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andrew R. Neill
Mr. Andrew R. Neill
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Abhinav A. Shukla, Ph.D.
Dr. Abhinav A. Shukla, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
+36.07%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
86.28K
+17.43%
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
81.47K
-8.97%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Prosight Capital
13.86%
OrbiMed Advisors, LLC
13.16%
Redmile Group, LLC
11.56%
Adage Capital Management, L.P.
9.76%
Hornblower Capital Holdings, LLC
6.04%
Other
45.62%
Shareholders
Shareholders
Proportion
Prosight Capital
13.86%
OrbiMed Advisors, LLC
13.16%
Redmile Group, LLC
11.56%
Adage Capital Management, L.P.
9.76%
Hornblower Capital Holdings, LLC
6.04%
Other
45.62%
Shareholder Types
Shareholders
Proportion
Hedge Fund
28.47%
Investment Advisor/Hedge Fund
17.06%
Private Equity
13.16%
Corporation
12.56%
Investment Advisor
8.13%
Family Office
3.74%
Individual Investor
2.44%
Research Firm
1.52%
Other
12.91%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
179
32.74M
68.35%
-1.53M
2025Q2
186
35.33M
73.76%
-6.35M
2025Q1
190
36.10M
75.45%
-5.76M
2024Q4
182
37.00M
77.49%
-7.77M
2024Q3
191
41.87M
87.75%
-1.86M
2024Q2
194
39.66M
83.35%
+16.66K
2024Q1
209
37.10M
79.60%
-1.39M
2023Q4
203
34.54M
71.04%
+5.75M
2023Q3
205
27.35M
64.28%
-7.93M
2023Q2
215
27.61M
64.91%
-8.42M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Prosight Capital
6.64M
13.86%
--
--
Jun 30, 2025
OrbiMed Advisors, LLC
6.31M
13.16%
+6.31M
--
Sep 02, 2025
Redmile Group, LLC
5.54M
11.56%
--
--
Aug 25, 2025
Adage Capital Management, L.P.
4.67M
9.76%
--
--
Jun 30, 2025
Hornblower Capital Holdings, LLC
2.89M
6.04%
--
--
Apr 01, 2025
Houghton Capital Holdings, LLC
2.61M
5.45%
--
--
Apr 01, 2025
The Vanguard Group, Inc.
2.15M
4.48%
-252.36K
-10.51%
Jun 30, 2025
The Clark Estates Inc.
1.48M
3.08%
--
--
Jun 30, 2025
Pinnacle Associates Ltd.
1.36M
2.85%
+64.00K
+4.92%
Jun 30, 2025
683 Capital Management LLC
1.09M
2.29%
+45.00K
+4.29%
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
Texas Capital Texas Equity Index ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares UltraPro Russell2000
0%
Dimensional US Core Equity 1 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Morningstar Small-Cap ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Texas Capital Texas Small Cap Equity Index ETF
0%
View more
Texas Capital Texas Equity Index ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Morningstar Small-Cap ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Texas Capital Texas Small Cap Equity Index ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
